Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: J Pediatr Gastroenterol Nutr. 2014 Feb;58(2):215–221. doi: 10.1097/MPG.0b013e3182a98df2

Table 2.

Comparison of outcomes between IBD subtypes

CD n=12 UC/IBD-U n=17 Difference of Proportions [95% CI] P-value
26 week steroid-free remission 5 (42%) 7 (41%) 1% [−36%, 37%] 0.98
52 week steroid-free remission 5 (42%) 7 (41%) 1% [−36%, 37%] 0.98
Infliximab dose escalation 8 (67%) 10 (59%) 8% [−28%, 43%] 0.67
Infliximab failure 6 (50%) 12 (71%) −21% [−56%, 15%] 0.26
Colectomy 5 (42%) 7 (41%) 1% [−36%, 37%] 0.98

CI, confidence interval